Frontiers of COVID-19-related myocarditis as assessed by cardiovascular magnetic resonance

Coronavirus disease 2019(COVID-19)is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.In some patients,COVID-19 is complicated with myocarditis.Early detection of myocardial injury and timely intervention can significantly improve the clinical outcomes of COVID-19 patients.Although endomyocardial biopsy(EMB)is currently recognized as the‘gold standard’for the diagnosis of myocarditis,there are large sampling errors,many complications and a lack of unified diagnostic criteria.In addition,the clinical methods of treating acute and chronic COVID-19-related myocarditis are different.Cardiac magnetic resonance(CMR)can evaluate the morphology of the heart,left and right ventricular functions,myocardial perfusion,capillary leakage and myocardial interstitial fibrosis to provide a noninvasive and radiation-free diagnostic basis for the clinical detection,efficacy and risk assessment,and followup observation of COVID-19-related myocarditis.However,for the diagnosis of COVID-19-related myocarditis,the Lake Louise Consensus Criteria may not be fully applicable.COVID-19-related myocarditis is different from myocarditis related to other viral infections in terms of signal intensity and lesion location as assessed by CMR,which is used to visualize myocardial damage,locate lesions and quantify pathological changes based on various sequences.Therefore,the standardized application of CMR to timely and accurately evaluate heart injury in COVID-19-related myocarditis and develop rational treatment strategies could be quite effective in improving the prognosis of patients and preventing potential late-onset effects in convalescent patients with COVID-19.